The purpose of the prospective, randomized, double blind, placebo-controlled multicenter
pilot study is to evaluate the effectiveness of abciximab on rescuing the hypoperfused brain
tissue, as assessed by MRI, and the relative safety of abciximab in patients with wake-up
stroke.
Phase:
Phase 3
Details
Lead Sponsor:
University of Zurich
Collaborator:
Eli Lilly and Company
Treatments:
Abciximab Antibodies, Monoclonal Immunoglobulin Fab Fragments